Denis Horgan
YOU?
Author Swipe
View article: From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies?
From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? Open
Over the past two decades, precision oncology has seen unprecedented advances, particularly with the rise of small molecule drugs. These drugs have significantly benefitted patients with cancer harboring somatic genomic alterations, contri…
View article: Precision Oncology: A Global Perspective on Implementation and Policy Development
Precision Oncology: A Global Perspective on Implementation and Policy Development Open
Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient seg…
View article: Understanding the Landscape of Cancer Care in Europe: Evaluating Clinical and Comprehensive Cancer Centers
Understanding the Landscape of Cancer Care in Europe: Evaluating Clinical and Comprehensive Cancer Centers Open
Background: A comparison of the operations of Clinical Cancer Centers and Comprehensive Cancer Centers across Europe provides novel data on the interrelation between different factors in care delivery. Method: The analysis is based on a su…
View article: Welcoming the future: embracing novel technologies for a progressive health system
Welcoming the future: embracing novel technologies for a progressive health system Open
View article: Genetic counselling legislation and practice in cancer in EU Member States
Genetic counselling legislation and practice in cancer in EU Member States Open
Background Somatic and germline genetic alterations are significant drivers of cancer. Increasing integration of new technologies which profile these alterations requires timely, equitable and high-quality genetic counselling to facilitate…
View article: A Vision for Democratizing Next-Generation Oncology Clinical Trials
A Vision for Democratizing Next-Generation Oncology Clinical Trials Open
Summary: Revolutionary advancements in oncology have transformed lives, but the clinical trials ecosystem encounters challenges, including restricted access to innovative therapies and a lack of diversity in participant representation. A v…
View article: Demographic Analysis of Cancer Research Priorities and Treatment Correlations
Demographic Analysis of Cancer Research Priorities and Treatment Correlations Open
Understanding the diversity in cancer research priorities and the correlations among different treatment modalities is essential to address the evolving landscape of oncology. This study, conducted in collaboration with the European Cancer…
View article: Addressing disparities in European cancer outcomes: a qualitative study Protocol of the BEACON project
Addressing disparities in European cancer outcomes: a qualitative study Protocol of the BEACON project Open
Introduction Health disparities represent a crucial factor in cancer survival rates, awareness, quality of life, and mental health of people receiving a cancer diagnosis and their families. Income, education, geographic location, and ethni…
View article: Aligning Cancer Research Priorities in Europe with Recommendations for Conquering Cancer: A Comprehensive Analysis
Aligning Cancer Research Priorities in Europe with Recommendations for Conquering Cancer: A Comprehensive Analysis Open
Improvements in cancer care require a new degree of collaboration beyond the purely medical sphere, extending deeply into the world of other stakeholders—preeminently patients but also the other stakeholders in the hardware and software of…
View article: Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems
Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems Open
View article: Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?
Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be? Open
View article: Mobilising Collaboration among Stakeholders to Optimise the Growing Potential of Data for Tackling Cancer
Mobilising Collaboration among Stakeholders to Optimise the Growing Potential of Data for Tackling Cancer Open
Effective cancer diagnosis, treatment and control depend on interactions among numerous distinct factors, from technology to data to skills to sociology. But a crucial influence is the extent to which the health system takes account of the…
View article: B1MG D1.6 Citizen engagement and public trust in genomic data sharing
B1MG D1.6 Citizen engagement and public trust in genomic data sharing Open
<p>The '1+ Million Genomes' (1+MG) initiative, coordinated by the Beyond 1 Million Genomes (B1MG) project, aims to enable secure access to genomic and corresponding clinical data across Europe for research, personalised healt…
View article: Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicine
Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicine Open
Growing awareness of the genetic basis of disease is transforming the opportunities for improving patient care by accelerating the development, delivery and uptake of personalised medicine and diseases diagnostics. This can mean more preci…
View article: Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium
Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium Open
View article: Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area
Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area Open
Radical new possibilities of improved treatment of cancer are on offer from an advanced medical technology already demonstrating its significance: next-generation sequencing (NGS). This refined testing provides unprecedentedly precise diag…
View article: Fighting Cancer around the World: A Framework for Action
Fighting Cancer around the World: A Framework for Action Open
Tackling cancer is a major challenge right on the global level. Europe is only the tip of an iceberg of cancer around the world. Prosperous developed countries share the same problems besetting Europe–and the countries and regions with few…
View article: How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis
How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis Open
Typically, PRS accuracy is comparable to PSA or family history with a pooled AUC value 0.63 indicating mediocre performance for PRS alone.
View article: Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring
Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring Open
Liquid biopsy (LB) is a minimally invasive method which aims to detect circulating tumor-derived components in body fluids. It provides an alternative to current cancer screening methods that use tissue biopsies for the confirmation of dia…
View article: Tackling Mantle Cell Lymphoma in Europe
Tackling Mantle Cell Lymphoma in Europe Open
An expert panel convened by the European Alliance for Personalized Medicine (EAPM) reflected on achievements and outstanding challenges in Europe in mantle cell lymphoma (MCL). Through the prism of member state experience, the panel noted …
View article: European Health Data Space—An Opportunity Now to Grasp the Future of Data-Driven Healthcare
European Health Data Space—An Opportunity Now to Grasp the Future of Data-Driven Healthcare Open
The May 2022 proposal from the European commission for a ‘European health data space’ envisages advantages for health from exploiting the growing mass of health data in Europe. However, key stakeholders have identified aspects that demand …
View article: How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?
How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma? Open
Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for significant improvements in diagnosis and c…
View article: Tackling Thyroid Cancer in Europe—The Challenges and Opportunities
Tackling Thyroid Cancer in Europe—The Challenges and Opportunities Open
Thyroid cancer (TC) is the most common malignancy of the endocrine system that affects the thyroid gland. It is usually treatable and, in most cases, curable. The central issues are how to improve knowledge on TC, to accurately identify ca…
View article: Making Sure That Orphan Incentives Tip the Right Way in Europe
Making Sure That Orphan Incentives Tip the Right Way in Europe Open
The delicate balance of funding research and development of treatments for rare disease is only imperfectly achieved in Europe, and even the current provisional equilibrium is under a new threat from well-intentioned policy changes now in …
View article: Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?
Towards Better Pharmaceutical Provision in Europe—Who Decides the Future? Open
Significant progress has been achieved in human health in the European Union in recent years. New medicines, vaccines, and treatments have been developed to tackle some of the leading causes of disease and life-threatening illnesses. It is…
View article: Meeting the Need for a Discussion of Unmet Medical Need
Meeting the Need for a Discussion of Unmet Medical Need Open
As Europe and the world continue to battle against COVID, the customary complacency of society over future threats is clearly on display. Just 30 months ago, such a massive disruption to global lives, livelihoods and quality of life seemed…
View article: B1MG D1.5 Stakeholders trust in genomic data sharing landscape analysis
B1MG D1.5 Stakeholders trust in genomic data sharing landscape analysis Open
<p>This scoping report represents a mission-oriented approach to supporting citizens' engagement and public trust in genomic data sharing, scoping out and suggesting possible approaches. It recognises from the outset that the iss…
View article: Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare
Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare Open
The potential for the use of real-world data (RWD) to generate real-world evidence (RWE) that can inform clinical decision-making and health policy is increasingly recognized, albeit with hesitancy in some circles. If used appropriately, t…
View article: Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe
Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe Open
Next-generation sequencing (NGS) may enable more focused and highly personalized cancer treatment, with the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines now recommending NGS for daily clinical …
View article: EU health policy is on the brink of a spectacular own-goal that will harm patients and hamper innovation
EU health policy is on the brink of a spectacular own-goal that will harm patients and hamper innovation Open
Article EU health policy is on the brink of a spectacular own-goal that will harm patients and hamper innovation was published on January 1, 2022 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 60, issue 1).